November 3, 2015 5:13pm

 

The “pattern” is so busy that investors should wait to enter; instructions are to hang out before the next turn

Line up downwind with the runway.  Subscription required, read more … http://www.regmedinvestors.com/user/register

 

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

U.S. stocks closed higher Tuesday, off session highs, supported by gains in energy and tech stocks.

The NASDAQ closed UP +17.98 or +0.35% to 5,145.13 and the DOW closed UP +89.39 or +0.50% to 17,918.15.

 

 

Henry’omics:

The stem, cell and gene therapy RegMed sector tried to hold Monday’s higher positions as traders sold into readily available strength.

  • However, the small-cap sector — considered the real engine of a healthy economy’s growth is off 8.5% from its highest closing level. A strong start for the Russell 2000 on Monday was a good sign, if the sector can maintain its momentum in November.

I worry about the lessons learned in the past months – let’s not portend to expect it to stay that way!

  • With financial results being prepared for dissemination in the days ahead – be prepared for a deep breath and a cautious dive in a riptide current;
  • In my belief, it’s so good it’s bad (or going to be) as the iShares Nasdaq Biotechnology ETF (IBB) jumped on Tuesday +0.30% following Monday’s advance of +3.87% when it had closed Friday DOWN -3.09 or -0.94%.  Are we headed back?

Volatility <VIX> indices have been declining since late August, and have had three separate VIX “spike peak” buy signals since then. The most recent VIX decline started in late September and it is the one that taken VIX back to bull market levels, towards 14 or so. As long as VIX remains at these relatively low levels, it is not a hindrance towards higher stock prices. VIX would have to climb above its declining 20- day moving average (currently at about 17) in order to indicate a potentially bearish change of trend for stocks <Lawrence G McMillan>;

  • My interpretation of the fear index, the CBOE Volatility Index (VIX) closed on Tuesday near 14 following Monday’s below 14 following Friday’s near 15.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

Market breadth has become the weakest of current indicators;

  • Market Breadth is a technique used in technical analysis that attempts to gauge the direction of the overall market by analyzing the number of companies advancing relative to the number declining;
  • Breadth has generally been a problem since the summer of 2014, and it still is a problem.

The SCGT & RM equities opened positive with an Advance/Decline line (A/DL) of 24/14 and 5 flats as compared to Monday’s 32/8 and 3 flats. The first hour flipped to negative with an A/DL of 17/15 and 5 flats;.  

 

  • The mid-day jumped to an A/DL of 26/15 and 2 flats.  The 3 pm A/DL maintained an upside by a hair at 27/15 and 1 flat;
  • The closing bell rang positive to end the session with an A/DL of 26/13 and 4 flats.

 

 

Tuesday’s follow-up on Monday’s eighteen (18) stocks jumping to the upside - $’s up as compared to Friday’s close:

  • bluebird bio (BLUE) – closed up Tuesday +$9.26 after Monday’s+$7.25 having closed down <Friday> -$1.96 ;
  • Cellectis ADR (CLLS) – closed up Tuesday +$7.24 after Monday’s +$4.89 having closed up <Friday> +$0.36;
  • Kite Pharma (KITE) closed up on Tuesday +$0.32 after Monday’s +$4.28 having closed down <Friday> -$0.72;
  • Spark Therapeutics (ONCE) closed down -$0.82 after Monday’s +$4.18 having closed down <Friday> -$1.21;
  • Bellicum (BLCM) closed up on Tuesday +$0.24 after Monday’s +$2.33 having closed down <Friday> -$0.50;
  • Intrexon (XON) closed up on Tuesday +$3.90 after Monday’s +$1.92 having closed down <Friday> -$0.13;
  • Juno Therapeutics (JUNO) closed up +$2.14 after Monday’s +$1.90 having closed up <Friday> +$0.37;
  • uniQure (QURE) closed up +$0.25 on Tuesday after Monday’s +$1.05 having closed down <Friday> -$0.13;
  • Osiris (OSIR) closed down -$0.30 on Tuesday after Monday’s +$1.05 having closed up <Friday> +$0.60;
  • Applied Genetic Technologies (AGTC) closed up +$0.05 on Tuesday after Monday’s +$1.03 having closed down <Friday> -$0.08;
  • Regenxbio (RGNX) up +$0.69 on Tuesday after Monday’s +$0.98 having closed down <Friday> -$0.13;
  • Sangamo (SGMO) closed up +$0.02 on Tuesday after Monday’s +$0.83 having closed down <Friday> +$0.64;
  • Aduro Biotech (ADRO) closed up +$0.08 after Monday’s +$0.74 having closed up <Friday> +$0.11;
  • Avalanche (AAVL) closed up +$0.23 on Tuesday after Monday’s +$0.62 having closed down <Friday> +$0.03;
  • MiMedx (MDXG) closed down -$0.42 0n Tuesday after Monday’s +$0.53 having closed down <Friday> -$0.01;
  • Asterias Therapeutics (NYSEMKT: AST) closed down -$0.07 on Tuesday after Monday’s +$0.50 having closed down <Friday> +$0.33;
  • Fibrocell FCSC) closed UP +$0.16 on Tuesday after Monday’s +$0.46 having closed down <Friday> -$0.28;

 

 

Dosing the sector – what a day for the 43 Patients:

  • Open: POSITIVE with 14 decliners, 24 advances and 5 flats;
  • Mid-day (1 pm): POSITIVE with 15 decliners, 26 advancers and 2 flats;
  • 3 pm: POSITIVE with 15 decliners, 27 advancers and 1 flat;
  • Closing bell: POSITIVE with 13 decliner, 26 advancers and 4 flats

 

 

Riding the indexes and ETFs roller-coaster:

  • The iShares Biotechnology Stocks ETF (IBB) closed UP +1.02 or +0.30% on Tuesday following Monday’s advance of +12.60 or +3.87% after Friday’s decline of -3.09 or -0.94%;
  • The NASDAQ Biotechnology index (NBI) closed UP +3.74 or +0.11% following Monday’s advance of +131.08 or +3.84% after Friday’s decline of- 31.55 or -0.92%;
  • The Russell 2000 (IWM) closed UP +0.61 or +0.52% following Monday’s +2.40 or +2.08% after Friday’s decline of -0.43 or -0.46%;
  • The SPDR SD&P Biotech ETF (XBI) closed UP on Tuesday +0.64 or +0.90% following Monday’s advance of +4.48 or +5.72% after Friday’s decline of -0.68 or -1.01%;

 

 

Who closed down – top 5:

  • Spark Therapeutics ONCE) closed down -$0.82 to $57.26;
  • VistaGen (VSTA) -$0.48 to $7.00;
  • MiMedx (MDXG) -$0.42 to $7.39;
  • Osiris (OSIR) -$0.030 to $17.78;
  • Fate therapeutics (FATE) closed down -$0.13 to $17.78

 

 

Who was UP – top 5:

  • Bluebird bio (BLUE) closed up +$9.26 to $93.64;
  • Cellectis ADR (CLS) +$7.24 to $38.58;
  • Intrexon (XON) +$3.90 to $39.42;
  • Juno therapeutics (JUNO) +$2.14 to $55.80;
  • Regenxbio (RGNX) close up +$0.69 to $17.13

 

 

Flat:

  • Capricor (CAPR) at $4.07;
  • Cytori (CYTX) at $0.37;
  • Mesoblast ADR (USOTC: MBLTY) at $12.33;
  • StemCells (STEM) at $0.40;

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.